YK11

Popis

Popis produktu:

Formulation: The product is presented in a liquid form, available in a 50 ml vial, with a concentration of 25 mg/ml. This results in a total active ingredient content of 50 x 25 mg, which equals 1250 mg of the active compound.

Chemické informace:
– Molecular Weight (M.Wt): 389.33 g/mol
– Chemický vzorec: C₁₉H₁₄F₃N₃O₃
– Číslo CAS: 841205-47-8

Physical Properties:
– Solubility: The compound is soluble in polyglycols, facilitating its application in various pharmaceutical and biochemical formulations.
– Čistota: The product boasts a purity of >99%, ensuring high-quality standards for effective use.

Storage Conditions: To maintain the integrity of the product, it should be stored at 20℃. The product has a shelf life of 2 roky under these storage conditions.

Pharmacological Data:
– Half-Life: The substance has a half-life of 24 hours, indicating that it remains active in the system for an extended period, which could be relevant for dosing schedules.

This description includes all relevant information while emphasizing key details for clarity. Adjust any sections as necessary to fit the intended context or additional information you may have.

Non hai fornito un nome specifico per il composto chimico, quindi non posso fornire referenze specifiche per l’ingrediente. Tuttavia, l’ingrediente sembra essere Ostarine (MK-2866 o Enobosarm), un modulatore selettivo del recettore degli androgeni (SARM) usato per il potenziamento delle prestazioni sportive e il trattamento di condizioni mediche come l’atrofia muscolare.

Basandomi su questa informazione, le seguenti fonti scientifiche possono essere utili:

1. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle. 2011;2(3):153-161.
2. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences. 2013;68(1):87-95.
3. Srinath R, Dobs A. Enobosarm (GTx-024, S-22): a potential treatment for cachexia. Future Oncology. 2014;10(2):187-194.